Obesity causes organ dysfunction via several pathophysiological mechanisms, ranging from the physical impact of increased adipose tissue mass, the presence of ectopic fat within tissues and organs, metabolic effects, inflammatory mechanisms, and psychological consequences [4,5]
For patients experiencing genuine tachyphylaxis despite optimized lifestyle changes, switching to a dual-compound therapy like GLP-Squared Injection (semaglutide + tirzepatide) can reignite progress
They did however comment in their New England Journal of Medicine article that the affinity of lixisenatide for the GLP-1 receptor was up to four times greater than that of human GLP-1and there have been neuroprotective actions shown in animal models of Alzheimers disease. Together, I suspect these were likely strong rationales driving their choice of the use of Lixisenatide
Your GLP-1 dosage is gradually adjusted based on how your body responds, including appetite changes, digestive tolerance, energy levels, and overall progress